Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Quentin Anstee

Newcastle AuthorsTitleYearFull text
Professor Quentin Anstee
A data-driven framework reconstructs the molecular continuum of human MASLD progression2026
Professor Quentin Anstee
Dr Dina Tiniakos
Professor Fiona Oakley
EASL position paper on preclinical models of steatotic liver disease2026
Professor Arun Sanyal
Professor Quentin Anstee
Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH2026
James Clark
Dr Simon Cockell
Emerita Professor Ann Daly
Professor Dina Tiniakos
Professor Quentin Anstee
et al.		Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis2026
Tomos Robinson
Dr Hangjian Wu
Professor Cliff Brass
Kristy Wonders
Professor Luke Vale
et al.		Mapping the NASH-CHECK to the EQ-5D-5L in a MASLD population in seven European countries2026
Professor Quentin Anstee
Non-invasive tests in Metabolic-dysfunction Associated Steatotic Liver Disease: the prospective, multi-centre LITMUS Study2026
Kristy Wonders
Dr Dina Tiniakos
Professor Quentin Anstee
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: The LITMUS Imaging Study2026
Dr Cary Au
Professor Quentin Anstee
Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests2026
Professor Dina Tiniakos
Professor Pierre Bedossa
Dr Alasdair Blain
Kristy Wonders
Professor Quentin Anstee
The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD2026
Dr Kate Hallsworth
Professor Quentin Anstee
Dr Leah Avery
Helen Jarvis
Dr Dina Mansour
et al.		The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus2026
Professor Quentin Anstee
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective2025
Professor Quentin Anstee
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease2025
Professor Quentin Anstee
ECM formation and degradation during fibrosis, repair, and regeneration2025
Professor Quentin Anstee
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis( MIRNA): results from the phase 2, randomised, double-blind, double-dummy study2025
Rachel Howarth
Thomas Crame
Professor Stuart McPherson
Professor Quentin Anstee
Laura Haigh
Food Insecurity Is Highly Prevalent Amongst Patients With Chronic Liver Disease in Northern England: A Cross-Sectional Analysis2025
1234567891011121314151617181920...>>